Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: A randomised, double-blind study

被引：68

作者：

Jungheinrich C. ^{[1
]}

Sauermann W. ^{[2
]}

Bepperling F. ^{[1
]}

Vogt N.H. ^{[3
]}

机构：

[1] Clinical Research, D-61346 Bad Homburg, Fresenius Kabi

[2] DATAMAP GmbH Biostatistics Inst., Freiburg

[3] Department of Anaesthesiology, St Hedwig Hospital, Berlin

来源：

Drugs in R & D | 2004年 / 5卷 / 1期

关键词：

Factor VIII; Hydroxyethyl Starch; Colloid Osmotic Pressure; Vecuronium Bromide; Coagulation Factor VIII;

D O I：

10.2165/00126839-200405010-00001

中图分类号：

学科分类号：

摘要：

Background and objective: Different types of hydroxyethyl starch (HES) affect blood coagulation differently. We studied the effects of HES 130/0.4 on coagulation in major orthopaedic surgery in relation to the pharmacological parameter in vivo molecular weight. Methods: 52 patients were randomly allocated to either HES 130/0.4 (6%, mean molecular weight 130 kDa, molar substitution 0.4) or HES 200/0.5 (6%, control) in a double-blind fashion. Colloidal volume requirements for intra- and postoperative haemodynamic stabilisation were compared. Safety analyses of this pharmacological study included a comparison of coagulation factor tests, in vivo molecular weight, and HES plasma concentrations. Results: The colloidal volumes given were similar at the end of surgery (1602 ± 569 for HES 130/0.4 vs 1635 ± 567mL for HES 200/0.5), 5h later (1958 ± 467 vs 1962 ± 398mL), and up to the first postoperative day (2035 ± 446 vs 2000 ± 424mL). HES in vivo molecular weight at the end of surgery was 88 707 ± 13 938 versus 158 374 ± 33 933Da (p < 0.001) and 5h later was 86 663 ± 16 126 versus 136 299 ± 26 208Da (p < 0.001). In parallel to the lower in vivo molecular weight, factor VIII and von Willebrand factor returned to almost normal in the HES 130/0.4 group up to 5h postoperatively, but not in the control group (p < 0.05). Residual HES plasma concentrations after 24h were low in the HES 130/0.4 group (1.0 mg/mL), but higher in the control group (2.6 mg/mL). Conclusion: HES 130/0.4 and HES 200/0.5 were found to be similar with regard to volume efficacy. Sensitive coagulation parameters returned more rapidly to normal in the HES 130/0.4 group. Lower in vivo molecular weight and more rapid excretion of HES 130/0.4 are the likely explanations for the smaller influence on coagulation in this group.

引用

页码：1 / 9

页数：8

共 21 条

[1]

Boldt J., Haisch G., Suttner S., Et al., Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend®) on measures of coagulation, Br. J. Anaesth., 89, pp. 722-728, (2002)

[2]

Vogt N.H., Bothner U., Lerch G., Et al., Large-dose administration of 6% hydroxyethyl starch 200/0.5 in total hip arthroplasty: Plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin, Anesth. Analg., 83, pp. 262-268, (1996)

[3]

Stump D.C., Strauss R.G., Henriksen R.A., Et al., Effects of hydroxy-ethyl starch on blood coagulation, particularly factor VIII, Transfusion, 25, pp. 349-354, (1985)

[4]

Jung F., Koscielny J., Mrowietz C., Et al., The effect of molecular structure of hydroxyethyl starch on the elimination kinetics and fluidity of blood in human volunteers, Arzneimittelforschung, 43, pp. 99-105, (1993)

[5]

Treib J., Haass A., Pindur G., Et al., HES 200/0.5 is not HES 200/0.5: Influence of the C2/C6 hydroxyethylation ratio of hydroxy-ethyl starch (HES) on hemorheology, coagulation and elimination kinetics, Thromb. Haemost., 74, pp. 1452-1456, (1995)

[6]

Gallandat Huet R.C., Siemons A.W., Baus D., Et al., A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery, Can. J. Anesth., 47, pp. 1207-1215, (2000)

[7]

Langeron O., Doelberg M., Ang E.T., Et al., Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5, Anesth. Analg., 92, pp. 855-862, (2001)

[8]

Haisch G., Boldt J., Krebs C., Et al., The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery, Anesth. Analg., 92, pp. 565-571, (2001)

[9]

Haisch G., Boldt J., Krebs C., Et al., Influence of a new hydroxyethyl starch preparation (HES 130/0.4) on coagulation in cardiac surgical patients, J. Candiothorac. Vasc. Anesth., 15, pp. 316-321, (2001)

[10]

Lang K., Boldt J., Suttner S., Et al., Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery, Anesth. Analg., 93, pp. 405-409, (2001)

← 1 2 3 →